Cardiovascular Endocrinology

MON-273 - Prevalence, Testing Patterns, and Clinical Management of Elevated Lipoprotein(A) in A Large Academic Health System

Monday, June 15, 2026

9:00 AM - 2:00 PM CT

Location: ENDOExpo; Poster Floor

Abstract Poster Presenter(s)

Marc-Andre Cornier, MD

Professor of Medicine
Medical University of South Carolina
Isle Of Palms, SC, United States

Senior Author/Primary Investigator(s)

Marc-Andre Cornier, MD

Professor of Medicine
Medical University of South Carolina
Isle Of Palms, SC, United States

Co-Author(s)

LS

Lori Spillers, RN

Nurse Administrator
MUSC
Charleston, South Carolina, United States
LR

Lexie Rasco, MD

MUSC
Charleston, United States
EM

Ethan Mitchel, n/a

MUSC
Charleston, United States
XZ

Xueqing Zhang, MD

MUSC
Charleston, South Carolina, United States
GM

Ghada Mohamed, MD

Emory University
Atlanta, United States
MJ

Miran Jaffa

MUSC

Disclosure(s):

Marc-Andre Cornier, MD: Amgen: Grant Recipient (); Aztra Zeneca: Consultant (), Grant Recipient (); Biophytis: Advisory Board (); Bonus Health: Consultant (); Cleerly: Grant Recipient (); Enveda: Consultant (); Ionis: Grant Recipient (); Kaneka: Grant Recipient (); Keros: Consultant (); Lilly: Advisory Board (); Novartis: Grant Recipient (); Novo Nordisk: Advisory Board (); Rivus: Consultant (); wave: Consultant (); Zyversa: Consultant ()

Background: Elevated lipoprotein(a) [Lp(a)] is an established causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite guideline recommendations for at least one lifetime measurement, real-world testing patterns remain largely undefined.

Methods: We conducted a retrospective analysis of adults receiving care within the Medical University of South Carolina (MUSC) Health System between 2017–2022. We assessed Lp(a) testing prevalence, patient characteristics, lipid parameters, clinical comorbidities, and medication patterns. Patients with Lp(a) ≥75 nmol/L were compared with those with lower levels.

Results: Among 1,364,178 patients, only 692 (0.05%) had an Lp(a) measurement. Tested patients were older (mean 58.6 years), predominantly white (74%), and had high ASCVD burden (49.7%). Elevated Lp(a) was common (38.6%) in this tested population and was more frequent among Black patients. Patients tested for Lp(a) were more likely to have ASCVD (49.7%) than the general population (8.34%) and nearly half had been seen by a cardiologist or lipid specialist. Lipid-lowering therapy use was common among tested patients (statins 70%, ezetimibe 27%), but PCSK9 inhibitor use remained low overall (11.9%) .

Conclusion: Lp(a) testing was uncommon at MUSC, occurring primarily among high-risk individuals already engaged in specialty care. Elevated Lp(a) was associated with distinct racial patterns. Significant opportunities exist to expand Lp(a) screening, standardize management pathways, and prepare for upcoming Lp(a)-lowering therapies. System-level strategies are needed to improve equitable identification and treatment of individuals with elevated Lp(a).

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*